---
title: "Policy Pulse — Global Spillover — 23 Jul 2026"
ticker: "XOM:CVX:OXY:HAL:SLB:DAL:UAL:AAL:LMT:NOC:GD:RTX:ONGC:OIL:IOC:BPCL:HPCL:MRPL:INFY:TCS:WIPRO:HCLTECH:INDIGO:CIPLA:DRREDDY:SUNPHARMA:LUPIN:WELSPUN:TRIDENT:VARDHMAN:TEVA:MYL:LLY:MRK:JNJ:ABBV:CCL:RCL"
date: "2026-07-23"
tags: ["policy-pulse","global","hormuz","oil","defence","earnings","infy","indigo","cipla","pharma","it","textiles","tariffs","section-122"]
summary: "INFY Q1: +12% PAT, guidance trimmed, ADR -4.85%. INDIGO: ₹238cr net loss on fuel costs (85% rise). CIPLA: -39% PAT. Hormuz: 12th night, Brent near 8. IOC/MRPL halt Iraq loadings. Section 122 expiry tomorrow benefits Indian IT/Textiles. ONGC gains, refiners bleed."
model: "deepseek-chat"
---

## 🌍 Global Spillover Watch — July 23, 2026

### 1. 🇮🇷 Hormuz Crisis — 12th Night of Strikes; Brent Near $98; IOC/MRPL Halt Iraq Loadings

The US-Iran conflict enters its 12th consecutive night of CENTCOM strikes. Houthi rebels targeted two Saudi oil tankers in the Red Sea. Brent crude surged to **$98/barrel** — a six-week high — while WTI tested $89. **Key Indian impact:** IOC and MRPL continue to halt Iraq crude loadings. Rupee slipped further to **96.57/USD** (-4 paise). 

**India-specific stock signals:**

| Stock | Impact | Reason |
|-------|--------|--------|
| ONGC | 🟢 Positive | Domestic crude producer directly benefits from $95+ Brent; substitution demand as refiners seek non-Gulf supply |
| OIL | 🟢 Positive | Same upstream benefit; higher crude realizations boost profitability |
| IOC | 🔴 Negative | Refiner hit by crude cost + Iraq supply disruption; forced to source costlier spot crude |
| BPCL | 🔴 Negative | Same crude cost pressure; diversified sourcing partially mitigates but margins compressed |
| HPCL | 🔴 Negative | Most exposed to under-recoveries; government may not fully pass through fuel price increases |
| MRPL | 🔴 Negative | Stopped Iraq loadings; margin pressure from higher feedstock costs; heavily Gulf-dependent |

**US stock signals:**

| Stock | Impact | Reason |
|-------|--------|--------|
| XOM | 🟢 Positive | $95+ Brent = record upstream margins |
| CVX | 🟢 Positive | Strong Permian production; 45%+ oil-linked |
| OXY | 🟢 Positive | Most leveraged to WTI among majors |
| HAL | 🟢 Positive | OFS demand rising |
| SLB | 🟢 Positive | Global OFS leader; Middle East activity rising |
| LMT | 🟢 Positive | F-35, warship, missile sustainment demand |
| NOC | 🟢 Positive | B-21, missile systems, electronic warfare |
| GD | 🟢 Positive | Shipbuilding + land systems |
| RTX | 🟢 Positive | Missiles and missile defense systems |
| DAL | 🔴 Negative | Jet fuel surging; international routes disrupted |
| UAL | 🔴 Negative | International-heavy; $98 Brent unprofitable for long-haul |
| AAL | 🔴 Negative | Fuel costs crushing margins |

---

### 2. 📊 Infosys Q1 FY27 Results — Net Profit +12% YoY, But Guidance Trimmed; CEO Succession Announced

**Infosys (INFY)** reported Q1 FY27 results after market close on July 23:

**Key numbers:**
- **Net profit:** ₹7,769 cr (+12.3% YoY, -8.6% QoQ)
- **Revenue:** ₹48,211 cr (+14% YoY, +3.9% QoQ); $5.08B (+0.8% QoQ CC)
- **EBIT margin:** 21.1% (+30 bps YoY, +10 bps QoQ)
- **Large deal wins:** $3.6B (vs $3.2B QoQ, vs $3.8B YoY)
- **AI revenue:** 8.2% of total revenue
- **Guidance:** FY27 CC revenue growth narrowed to 1.5%-3% (lowered upper end from 3.5%)
- **CEO succession:** Ashiss Kumar Dash named CEO-designate; will take over from Salil Parekh on April 1, 2027
- **ADR reaction:** INFY ADR fell ~4.85% post-results

| Stock | Impact | Reason |
|-------|--------|--------|
| INFY | 🔴 Negative (Near-term) | Guidance trimmed + ADR -4.85% signals negative market reaction. Solid execution (21.1% margin, $3.6B deals) but growth outlook lowered |
| TCS | 🟡 Neutral | IT bellwether signal. TCS reports Aug 6. If Infosys guides conservatively due to macro, TCS likely similar tone |
| WIPRO | 🔴 Negative | Weaker IT demand signal from INFY guidance; Wipro already lagging peers |
| HCLTECH | 🟡 Neutral | HCL's business mix (engineering/R&D) less correlated; may weather macro better |
| TECHM | 🔴 Negative | Weaker macro = more pressure on smaller IT services firms |
| LTI | 🔴 Negative | Mid-cap IT most vulnerable to macro slowdown signals |

**Key insight for IT sector:** INFY trimmed guidance due to "uncertain macro environment" and "softer demand trends." This is consistent with HCLTECH and WIPRO recent commentary. However, $3.6B in large deal wins and AI now at 8.2% of revenue are positives. The near-term direction is negative for INFY specifically (guidance cut + ADR drop), but the broader IT sector outlook is cautiously neutral — AI deal momentum offsets macro weakness.

---

### 3. ✈️ IndiGo (InterGlobe Aviation) Q1 — ₹238 Cr Net Loss on Fuel Costs

IndiGo reported a **consolidated net loss of ₹238 crore** for Q1 FY27 (vs profit of ₹2,176 cr YoY), driven by an 85.7% surge in aircraft fuel expenses and rupee depreciation. Revenue grew 20% to ₹24,854 cr.

| Stock | Impact | Reason |
|-------|--------|--------|
| INDIGO | 🔴 Negative | Second straight quarterly loss; fuel costs + West Asia disruption crushing profitability. Stock -1.70% on the day |
| SPICEJET | 🟡 Neutral | Different story — surged 10% today on Adani Group and Gulf airline acquisition speculation; fundamentals remain weak |
| IAAIP (Air India) | 🔴 Negative | Same fuel cost pressure; likely similar Q1 result when reported |

**Key insight:** IndiGo's loss is directly attributable to the Hormuz conflict — fuel costs surged 85% YoY. If Brent stays near $100, Indian aviation faces a prolonged pain period. The government may need to consider ATF excise duty cuts or other relief measures.

---

### 4. 💊 Cipla Q1 — Net Profit -39% YoY; Pharma Sector Under Pressure

| Stock | Impact | Reason |
|-------|--------|--------|
| CIPLA | 🔴 Negative | Q1 profit -39% YoY to ₹789 cr; North American generic headwinds + tariff overhang. Stock -1.42% |
| DRREDDY | 🔴 Negative | Revenue decline 5.6% YoY + net profit -68.7%; North American pricing pressure |
| SUNPHARMA | 🟡 Neutral | Held up relatively well (+0.57% today); diversified portfolio less US-dependent |
| LUPIN | 🔴 Negative | US generic pricing pressure + tariff overhang |

**Key insight:** Cipla and Dr. Reddy's Q1 results confirm the structural pressure on Indian pharma — weak US generic pricing AND the recently announced Trump tariff timeline create a double headwind. The 2-year grace period provides some buffer, but the trajectory is clearly negative for US-focused generic players.

---

### 5. 🇺🇸 Section 122 Tariff Expires Tomorrow (Jul 24) — Global Trade Implications

The 10% Section 122 global import surcharge expires tomorrow. This has implications for:
- **India:** Indian exporters to the US benefit from removal of the 10% surcharge (IT services, pharma, textiles, auto parts)
- **China:** Section 122 tariffs applied to China too; expiry removes 10% but China already faces other tariffs
- **46-country Section 301:** Proposed 12.5% replacement still not finalized by USTR

| Stock | Impact | Reason |
|-------|--------|--------|
| TCS | 🟢 Positive | IT services exports to US; 10% surcharge removal benefits margins on US contracts |
| INFY | 🟢 Positive | Same dynamic — US revenue ~60%; tariff removal positive for margin |
| HCLTECH | 🟢 Positive | US revenue exposure; 10% cost reduction on services billed to US clients |
| WIPRO | 🟢 Positive | US revenue benefit from Section 122 expiry |
| WELSPUN | 🟢 Positive | Textile exports to US benefit from 10% duty removal |
| TRIDENT | 🟢 Positive | Same textile benefit |
| VARDHMAN | 🟢 Positive | Same textile benefit |

---

## 📋 Cross-Border Stock Signals Summary

| Region/Theme | Direction | Key Tickers | Narrative |
|--------------|-----------|-------------|-----------|
| Crude Oil (Hormuz) | 🟢 BUY US | XOM, CVX, OXY, HAL, SLB | Brent near $98; Hormuz closed; supermajor windfall |
| Defence (Hormuz) | 🟢 BUY US | LMT, NOC, GD, RTX | 12th night of strikes; sustained procurement |
| Airlines (Fuel) | 🔴 SELL US/IN | DAL, UAL, AAL, INDIGO | $98 Brent crushing margins; IndiGo ₹238 cr loss |
| Oil Upstream (India) | 🟢 BUY IN | ONGC, OIL | Domestic producers benefit from high crude |
| Oil Refiners (India) | 🔴 SELL IN | IOC, BPCL, HPCL, MRPL | Crude cost + Iraq supply disruption |
| Indian IT (Post INFY Q1) | 🔴 SELL near-term INFY; 🟡 Neutral sector | INFY, TCS, WIPRO, HCLTECH | INFY guidance trimmed; ADR -4.85%. AI deal momentum offsets macro caution |
| Indian Pharma (Earnings) | 🔴 SELL | CIPLA, DRREDDY, LUPIN | Weak Q1; US generic pricing pressure + tariff overhang |
| Indian Textiles (Section 122) | 🟢 BUY | WELSPUN, TRIDENT, VARDHMAN | 10% US surcharge removal benefits export margins |
| Section 122 Expiry | 🟢 BUY US Retail | WMT, TGT, COST, AMZN, HD, LOW | 10% import cost relief for largest US importers |
| Pharma Branded (Global) | 🟢 BUY | LLY, MRK, JNJ, ABBV | Protected by patent moat; generic tariff irrelevant |
| Pharma Generic (Global) | 🔴 SELL | TEVA, MYL | 200% tariff by 2029 is structural threat |